16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a 'radiation-first' strategy.

MLA

Moshfeghi, Andrew A., et al. “16 Gy Low-Voltage x-Ray Irradiation Followed by as Needed Ranibizumab Therapy for Age-Related Macular Degeneration: 12 Month Outcomes of a ‘Radiation-First’ Strategy.” The British Journal of Ophthalmology, vol. 96, no. 10, Oct. 2012, pp. 1320–24. EBSCOhost, https://doi.org/10.1136/bjophthalmol-2011-301222.

APA

Moshfeghi, A. A., Morales-Canton, V., Quiroz-Mercado, H., Velez-Montoya, R., Zavala-Ayala, A., Shusterman, E. M., Kaiser, P. K., Sanislo, S. R., Gertner, M., & Moshfeghi, D. M. (2012). 16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a “radiation-first” strategy. The British Journal of Ophthalmology, 96(10), 1320–1324. https://doi.org/10.1136/bjophthalmol-2011-301222

Chicago

Moshfeghi, Andrew A, Virgilio Morales-Canton, Hugo Quiroz-Mercado, Raul Velez-Montoya, Alicia Zavala-Ayala, Eugene Mark Shusterman, Peter K Kaiser, Steven R Sanislo, Michael Gertner, and Darius M Moshfeghi. 2012. “16 Gy Low-Voltage x-Ray Irradiation Followed by as Needed Ranibizumab Therapy for Age-Related Macular Degeneration: 12 Month Outcomes of a ‘Radiation-First’ Strategy.” The British Journal of Ophthalmology 96 (10): 1320–24. doi:10.1136/bjophthalmol-2011-301222.